eli lilly glp-1 agonist Ro, strike deal to offer lower-price vials of Zepbound Lilly's oral GLP-1 Foundayo (orforglipron)

Griffith D

And nobody has yet figured out what happens when genuinely effective obesity drugs become genuinely affordable at scale

Additionally, during covariate selection, age significantly affected the Emax value (Equation (7)) (Supplementary Fig

This guide is for patients who have been told they have fatty liver, elevated liver enzymes, MASLD, NAFLD, NASH, MASH, insulin resistance, prediabetes, type 2 diabetes, obesity, high triglycerides, or weight-related liver risk

Despite the side effects and murky insurance coverage, GLP-1s are becoming more common weight loss interventions

The transition toward oral delivery will be evolutionary, not disruptive, dependent on regulatory approvals, proven equivalence in cardiovascular outcomes, and competitive pricing